Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 55

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 55
---
 |     | $               | 13,800 |     | $     | 4,022,759 |
| Chief Medical Officer                               |     | 2023 |     | $      | 520,000 |     | $        | 269,093 |     | $               | 1,136,146 |     | $         | 2,230,744 |     | $               | 13,200 |     | $     | 4,169,183 |
|                                                     |     | 2022 |     | $      | 500,000 |     | $        | 225,000 |     | $               | 2,307,095 |     | $         | 2,647,757 |     | $               | 12,200 |     | $     | 5,692,052 |

(1) The amounts included in this column reflect bonus payments earned in 2022, 2023 and 2024.

(2) The amounts included in this column reflect the aggregate grant date fair value of RSUs granted during 2022, 2023 and 2024 based on the closing market price of the Company’s common stock on the date of grant.

(3) The amounts included in this column reflect the aggregate grant date fair value of stock options granted during 2022, 2023 and 2024 computed in accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation—Stock Compensation. The assumptions that we used to calculate these amounts are discussed in Note 9 to our audited Consolidated Financial Statements for the year ended December 31, 2024 included in our Annual Report on Form 10-K for the year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the NEO upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.

(4) The amounts included in this column reflect the dollar value of employer 401(k) matching contributions paid to each named executive officer.

<div align='center'>-41-</div>

#### Grants of Plan-Based Awards for Fiscal Year 2024
The following table provides information regarding grants of plan-based awards to our named executive officers during the fiscal year ended December 31, 2024.

| Name                      |     | Grant Date |     | All other stock awards: Number of shares of stock or units(1)